VGX 1027

Drug Profile

VGX 1027

Alternative Names: GIT 027; GIT-27; VGX-1027

Latest Information Update: 19 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoNOX
  • Developer GeneOne Life Science; Inovio Pharmaceuticals
  • Class Anti-inflammatories; Isoxazoles; Small molecules
  • Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Type 1 diabetes mellitus
  • Preclinical Ulcerative colitis; Uveitis

Most Recent Events

  • 28 May 2010 Preparation for phase II trials of VGX 1027 is still underway for type 1 Diabetes mellitus and Rheumatoid arthritis in USA
  • 14 May 2010 Inovio Biomedical is now called Inovio Pharmaceuticals
  • 01 May 2010 Preclinical trials in Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top